Convalescent plasma or hyperimmune immunoglobulin for people with COVID‐19: a living systematic review
Background Convalescent plasma and hyperimmune immunoglobulin may reduce mortality
in patients with viral respiratory diseases, and are currently being investigated in trials as …
in patients with viral respiratory diseases, and are currently being investigated in trials as …
COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review and meta-analysis
JW Senefeld, M Franchini, C Mengoli… - JAMA Network …, 2023 - jamanetwork.com
Importance Patients who are immunocompromised have increased risk for morbidity and
mortality associated with coronavirus disease 2019 (COVID-19) because they less …
mortality associated with coronavirus disease 2019 (COVID-19) because they less …
Retracted: COVID‐19 mortality and its predictors in the elderly: A systematic review
O Dadras, SA SeyedAlinaghi, A Karimi… - Health science …, 2022 - Wiley Online Library
Abstract Background and Aims Older people have higher rates of comorbidities and may
experience more severe inflammatory responses; therefore, are at higher risk of death …
experience more severe inflammatory responses; therefore, are at higher risk of death …
[HTML][HTML] The effect of convalescent plasma therapy on mortality among patients with COVID-19: systematic review and meta-analysis
To determine the effect of COVID-19 convalescent plasma on mortality, we aggregated
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …
patient outcome data from 10 randomized clinical trials, 20 matched control studies, 2 dose …
COVID-19 and tuberculosis coinfection: an overview of case reports/case series and meta-analysis
W Song, J Zhao, Q Zhang, S Liu, X Zhu, Q An… - Frontiers in …, 2021 - frontiersin.org
Background: Coronavirus disease 2019 (COVID-19) and tuberculosis (TB) are two major
infectious diseases posing significant public health threats, and their coinfection (aptly …
infectious diseases posing significant public health threats, and their coinfection (aptly …
Convalescent plasma therapy for COVID-19: state of the art
Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging
infectious diseases; its efficacy was later associated with the evidence that polyclonal …
infectious diseases; its efficacy was later associated with the evidence that polyclonal …
Use of convalescent plasma in COVID‐19 patients with immunosuppression
JW Senefeld, SA Klassen, SK Ford, KA Senese… - …, 2021 - Wiley Online Library
In the absence of effective countermeasures, human convalescent plasma has been widely
used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel …
used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel …
Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence
Background The triple burden of COVID-19, tuberculosis and human immunodeficiency
virus is one of the major global health challenges of the twenty-first century. In high burden …
virus is one of the major global health challenges of the twenty-first century. In high burden …
Global prevalence, treatment and outcome of tuberculosis and COVID-19 coinfection: a systematic review and meta-analysis (from November 2019 to March 2021)
Q Wang, S Guo, X Wei, Q Dong, N Xu, H Li, J Zhao… - BMJ open, 2022 - bmjopen.bmj.com
Introduction The COVID-19 outbreak poses a significant threat to the patients with
tuberculosis (TB). TB and COVID-19 (TB–COVID) coinfection means the disease caused by …
tuberculosis (TB). TB and COVID-19 (TB–COVID) coinfection means the disease caused by …
Immunotherapeutic approaches to curtail COVID-19
COVID-19, the disease induced by the recently emerged severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has imposed an unpredictable burden on the world. Drug …
coronavirus 2 (SARS-CoV-2), has imposed an unpredictable burden on the world. Drug …